saccharomyces boulardii and Reduced Incidence of Constipation

Doses used in studies

Safety in these studies

abdominal distentionIncreased riskRR = 0.39, 95% CI: 0.26-0.59
abdominal distention (RR = 0.39, 95% CI: 0.26-0.59)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba
constipationIncreased riskRR = 0.32, 95% CI: 0.18-0.55
constipation (RR = 0.32, 95% CI: 0.18-0.55)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba
diarrheaIncreased riskRR = 0.28, 95% CI: 0.22-0.36
Specifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba
nauseaIncreased riskRR = 0.59, 95% CI: 0.36-0.97
nausea (RR = 0.59, 95% CI: 0.36-0.97)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba
rashIncreased riskRR = 0.49, 95% CI: 0.28-0.86
rash (RR = 0.49, 95% CI: 0.28-0.86)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba
Overall tolerabilityReported
S. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62).
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicoba

2 of 2 papersPopulation:

The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.